Keji Pharmaceutical-B (02171): CT1190B completed the first patient infusion in a Phase I registered clinical trial in China

Zhitongcaijing · 4d ago

Zhitong Finance App News, Keji Pharmaceutical-B (02171) announced that CT1190B, a general-purpose CAR-T cell product targeting CD19/CD20, completed the first patient infusion in a phase I registered clinical trial in China to treat patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who failed at least second-line standard treatment. The results of the CT1190B IIT study were presented on a poster at the 2026 European Society of Hematology (EHA) Annual Meeting.